View Report
Our Rebates, Discounts and Fees in 2020
$29.4 billion—Rebates, discounts and fees provided in 2020 to payers and others in the health system— more than half the list price (53%) of our medicines.
Driving Treatment Advances for Patients
Between 2016-2020 we invested $42.2 billion in R&D.
Our R&D Investment Exceeds Our Spending on Marketing and Sales
Our R&D investment has increased an average of 8.1% for the past five years.
Our Discounts Have Grown From 2016-2020
Since 2016, the rebates and discounts we provide have nearly tripled, reflecting payers’ growing negotiating power.
Discounts to Government Programs Support Patient Access
We provide U.S. government programs with substantial discounts.
“We want disclosures like these to shape the conversation about how to sustain the innovation that’s the hallmark of the U.S. health system. That’s the legacy we’ve established with the Janssen U.S. Transparency Report and the legacy we are humbled to carry forward.”
Scott White, Company Group Chairman North America Pharmaceuticals, Johnson & Johnson
Scott White

Internet Explorer is not supported by this website.

For optimal browsing we recommend using Chrome, Safari, or Firefox.